1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Shionogi Deal Opens Asia To Sage’s Fast-Acting Antidepressant

 
• By Ian Haydock

Japan’s Shionogi has gained selected Asian rights to Sage’s promising fast-acting depression drug, in a deal worth up to $575m to the US company.

Human brain illustrated with millions of small nerves - Conceptual 3d render
ASIA DEAL FOR SAGE'S NOVEL ANTIDEPRESSANT • Source: Shutterstock

US company SAGE Therapeutics Inc. has struck the first licensing-out deal for its novel Phase II depression candidate SAGE-217, granting Japan’s Shionogi & Co. Ltd. exclusive development and commercialization rights in Japan, Taiwan and South Korea for $90m upfront.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia